Close

TGM2

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Transglutaminases are enzymes that catalyze the crosslinking of proteins by epsilon-gamma glutamyl lysine isopeptide bonds. While the primary structure of transglutaminases is not conserved, they all have the same amino acid sequence at their active sites and their activity is calcium-dependent. The protein encoded by this gene acts as a monomer, is induced by retinoic acid, and appears to be involved in apoptosis. Finally, the encoded protein is the autoantigen implicated in celiac disease.
  • CAR Vector Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAART-LX421 Anti-TGM2 (XHM495) h(CD28-CD3ζ) CAART, pCDCAAR1 Human XHM495 Human scFv-CD28-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
CAART-LX422 Anti-TGM2 (XHM495) h(4-1BB-CD3ζ) CAART, pCDCAAR1 Human XHM495 Human scFv-4-1BB-CD3ζ Lentiviral vector B cell   Add to Cart   Datasheet
XS-1222-ZP202 TGM2 (SDC4 Receptor) h(CD28-CD3ζ) Ligand-based CAR, pCDCAR1 Human TGM2-CD28-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1222-ZP1602 TGM2 (SDC4 Receptor) h(41BB-CD3ζ) Ligand-based CAR, pCDCAR1 Human TGM2-41BB-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.